Zydus announces Phase IV EVIDENCES-XI trial to generate RWE of Saroglitazar Mg in NAFLD patients…
Phase IV EVIDENCES- XI trial will enroll approximately 1500 NAFLD patients with comorbidities
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
non-alcoholic steatohepatitis
Successive drug launches will drive growth of NASH market in seven major markets: GlobalData
The NASH market will undergo a very rapid growth, at a compound annual growth rate (CAGR) of 68.8 per cent from 2019 to 2029